NCT01129557: Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease |
|
|
| Terminated | 4 | 46 | US | Aliskiren, Tekturna, Valsartan, Diovan | Columbia University, Novartis Pharmaceuticals | Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous | 01/12 | 12/12 | | |
| Completed | 4 | 32 | Europe | Aliskiren, Brand name: Ralisez, ATC-code: C09XA02, Moxonidine, No brand name (generic product), ATC-code: C02AC05, Hydrochlorothiazide, ATC-code: C03AA03, Placebo (for aliskiren), Placebo (for moxonidine and hydrochlorothiazide) | UMC Utrecht, Novartis Pharmaceuticals | Hypertension, Abdominal Obesity, Metabolic Syndrome | 02/12 | 02/12 | | |
